Cerebrospinal fluid pro-inflammatory cytokines differentiate parkinsonian syndromes.

J Neuroinflammation

Department of Neurology, Bispebjerg University Hospital, Bispebjerg Bakke 23, Copenhagen, Denmark.

Published: November 2018

Introduction: Neuroinflammation has been established to be part of the neuropathological changes in Parkinson's disease (PD) and atypical parkinsonism (APD). Activated microglia play a key role in neuroinflammation by release of cytokines. Evidence of the disparity, if any, in the neuroinflammatory response between PD and APD is sparse. In this study, we investigated CSF cytokine profiles in patients with PD, multiple system atrophy (MSA), or progressive supranuclear palsy (PSP).

Methods: On a sensitive electrochemiluminescence-based platform (Quickplex, Meso Scale Discovery®), we examined a panel of C-reactive protein (CRP) and eight selected cytokines, IFN-γ, IL-10, IL-18, IL-1β, IL-4, IL-6, TGF-β1, and TNF-α, among patients with PD (n = 46), MSA (n = 35), and PSP (n = 39) or controls (n = 31). Additionally, CSF total tau protein levels were measured as a marker of nonspecific neurodegeneration for correlation estimates.

Results: CRP and the pro-inflammatory cytokines TNF-α, IL-1β, and Il-6 were statistically significantly elevated in MSA and PSP patients compared to PD patients but not compared to control patients. No analytes differed statistically significantly between MSA and PSP patients. The best diagnostic discrimination, evaluated by ROC curve (AUC 0.77, p = 007, 95% CI 0.660-0.867), between PD and MSA patients was seen for a subset of analytes: CRP, TNF-α, IL-1β, and IFN-γ.

Conclusion: Among the investigated cytokines and CRP, we found a statistically significant increase of microglia-derived cytokines in MSA and PSP patients compared to PD patients.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6215346PMC
http://dx.doi.org/10.1186/s12974-018-1339-6DOI Listing

Publication Analysis

Top Keywords

msa psp
12
psp patients
12
patients compared
12
patients
9
pro-inflammatory cytokines
8
tnf-α il-1β
8
compared patients
8
cytokines
6
msa
6
cerebrospinal fluid
4

Similar Publications

Background And Objective: Non-motor symptoms frequently develop throughout the disease course of Parkinson's disease (PD), and pose affected individuals at risk of complications, more rapid disease progression and poorer quality of life. Addressing such symptom burden, the 2023 revised "Parkinson's disease" guideline of the German Society of Neurology aimed at providing evidence-based recommendations for managing PD non-motor symptoms, including autonomic failure, pain and sleep disturbances.

Methods: Key PICO (Patient, Intervention, Comparison, Outcome) questions were formulated by the steering committee and refined by the assigned authors.

View Article and Find Full Text PDF

Background: Progressive supranuclear palsy (PSP) is a major atypical parkinsonism. Because diagnosis based on the cardinal clinical features is often difficult, misdiagnosis with Parkinson's disease (PD) and multiple system atrophy (MSA) is common in PSP patients. Iron metabolism genes are reportedly involved in tau-accumulating neuronal cell death and ferroptosis in PSP, which is more severe than PD and MSA.

View Article and Find Full Text PDF

 Diagnosing movement disorders can be challenging owing to their similar clinical presentations with other neurodegenerative and basal ganglia disorders, like idiopathic Parkinson's disease (IPD), essential tremors (ET), vascular parkinsonism, multiple system atrophy (MSA), and progressive supranuclear palsy (PSP). Technetium-99m labeled tropane derivative (99mTc-TRODAT-1) imaging can help in diagnosing Parkinson's disease at an early stage to help early initiation of the treatment. The current study aimed to evaluate the role of 99mTc-TRODAT-1 imaging in differentiating IPD and Parkinson-plus syndromes (PPS).

View Article and Find Full Text PDF

Spatial discrimination in patients with MSA, PSP, DIP, and VP with pain.

Sci Rep

December 2024

Department of Neurology, Dongtan Sacred Heart Hospital, Hallym University College of Medicine, 7, Keunjaebong-gil, Hwaseong, Gyeonggi-do, 18450, Republic of Korea.

Article Synopsis
  • * A study involving 79 patients revealed high percentages of pain in MSA (73.9%), PSP (50.0%), DIP (67.9%), and VP (66.7%), but found no significant differences in sensory discrimination thresholds (SDT) between those with and without pain.
  • * The research concluded that the scaling function did not play a significant role in the development of pain among the different parkinsonian disorders studied.
View Article and Find Full Text PDF

Cognitive impairment in Parkinson's disease and other parkinsonian syndromes.

J Neural Transm (Vienna)

November 2024

Department of Neurology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Stavrou Niarchou Av., University Campus, Ioannina, Greece.

Article Synopsis
  • This review discusses mild cognitive impairment in Parkinson's disease and atypical parkinsonian disorders, emphasizing the overlap in symptoms and recent diagnostic criteria.
  • It highlights how conditions like progressive supranuclear palsy, corticobasal degeneration, and multiple system atrophy can also lead to significant cognitive decline.
  • The use of biomarkers such as MRI, FDG-PET, and specific proteins is becoming crucial for early diagnosis and differentiating these disorders, indicating a need for ongoing research to improve diagnostic methods and treatment options.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!